Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Vor Biopharma clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA, China, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Brazil, Japan, Australia and EU (CTIS) registers with Vor Biopharma as lead sponsor. Synced 21 Nov 2026
3Current trials
1Recruiting now
1Drug in these trials
13Trial registers
At a glance

Vor Biopharma is the lead sponsor of 3 current clinical trials in our USA, China, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Brazil, Japan, Australia and EU (CTIS) registers. 1 is recruiting patients now. All registered phases are Phase 3. The drugs named most often in its trials are Telitacicept. The most-studied condition is Primary Sjogren's Disease.

ClinicalTrials.gov trials by status

  • Recruiting150%
  • Active, closed150%

Trials by phase

  • Phase 32100%
01

Clinical trials sponsored by Vor Biopharma

2 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865 · ClinicalTrials.gov ↗ · Primary Sjogren's Disease
Phase 3 Recruiting 2026-02 USA
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580 · Generalized Myasthenia Gravis
Phase 3 Active, closed 2024-07 USA, China, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Brazil, Japan, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Vor Biopharma in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Vor Biopharma as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjögren’s Disease
2026-525556-28-00 · CTIS ↗ · Immune System Diseases
Phase 3 Ongoing Poland, Spain, Hungary + 7 more
03

Drugs in Vor Biopharma trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in Vor Biopharma trials

2 conditions
Primary Sjogren's Disease1Generalized Myasthenia Gravis1
06

Questions about Vor Biopharma trials

How many clinical trials does Vor Biopharma sponsor?

Vor Biopharma is the lead sponsor of 2 current trials on ClinicalTrials.gov in our USA, China, France, Spain, Italy, Belgium, Poland, Czechia, Canada, Brazil, Japan and Australia registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 21 November 2026. Completed and withdrawn studies are not counted.

Are Vor Biopharma trials recruiting?

Yes. 1 of its 2 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Vor Biopharma testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Telitacicept (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.